Pfizer breaks ground on its new $236 million Chesterfield research campus
By Bryce Gray
St. Louis Post-Dispatch
Jun 27, 2017
CHESTERFIELD • After a competitive, multiyear process to identify a home for the project, pharmaceutical giant Pfizer Inc. broke ground Tuesday on a research campus in Chesterfield where it will hone development of medicine and vaccines.
The facility will both maintain and grow Pfizer’s local presence, retaining the company’s 450 current employees in the area while eventually creating 80 positions.
The 295,000 square feet of laboratory and office space at 875 West Chesterfield Parkway represents a $236 million investment and is projected to be completed in mid-2019.
Company and government officials at Tuesday’s groundbreaking ceremony said that the region helped secure the project thanks to its established relationship with Pfizer and the strong pool of qualified expertise it offers in biological sciences.
“We looked at opportunities on the West Coast, East Coast, the Research Triangle in North Carolina,” said John Ludwig, Pfizer’s senior vice president of BioTherapeutics Pharmaceutical Sciences.
“This was the right decision for Pfizer to make,” he said. “The trained workforce was already here.”
Read More